These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9765752)

  • 21. Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC.
    Evans WK
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):18-25; discussion 25-6. PubMed ID: 9556779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
    Breathnach OS; Georgiadis MS; Schuler BS; Pizzella P; Llorens V; Kasturi V; Steinberg SM; O'Neil K; Takimoto CH; Johnson BE
    Clin Cancer Res; 2000 Jul; 6(7):2670-6. PubMed ID: 10914708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956).
    Scagliotti GV; Smit E; Bosquee L; O'Brien M; Ardizzoni A; Zatloukal P; Eberhardt W; Smid-Geirnaerdt M; de Bruin HG; Dussenne S; Legrand C; Giaccone G;
    Lung Cancer; 2005 Oct; 50(1):91-6. PubMed ID: 16019107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.
    Ranson M; Davidson N; Nicolson M; Falk S; Carmichael J; Lopez P; Anderson H; Gustafson N; Jeynes A; Gallant G; Washington T; Thatcher N
    J Natl Cancer Inst; 2000 Jul; 92(13):1074-80. PubMed ID: 10880550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vinorelbine in advanced non-small cell lung cancer. A pharmacoeconomic review.
    Coukell AJ; Noble S; Faulds D
    Pharmacoeconomics; 1999 Apr; 15(4):405-17. PubMed ID: 10537959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of an algorithm for staging small-cell lung cancer can save one third of the initial evaluation costs.
    Richardson GE; Venzon DJ; Edison M; Brown M; Frame JN; Ihde DC; Johnson BE
    Arch Intern Med; 1993 Feb; 153(3):329-37. PubMed ID: 8280192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An estimate of the cost effectiveness of gemcitabine in stage IV non-small cell lung cancer.
    Evans WK
    Semin Oncol; 1996 Oct; 23(5 Suppl 10):82-9. PubMed ID: 8893888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost analysis of lung cancer management in South Western Sydney.
    Kang S; Koh ES; Vinod SK; Jalaludin B
    J Med Imaging Radiat Oncol; 2012 Apr; 56(2):235-41. PubMed ID: 22498199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer.
    Leighl NB; Shepherd FA; Kwong R; Burkes RL; Feld R; Goodwin PJ
    J Clin Oncol; 2002 Mar; 20(5):1344-52. PubMed ID: 11870178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death.
    Navaratnam S; Kliewer EV; Butler J; Demers AA; Musto G; Badiani K
    Lung Cancer; 2010 Oct; 70(1):110-5. PubMed ID: 20153911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer.
    Holmes J; Dunlop D; Hemmett L; Sharplin P; Bose U
    Pharmacoeconomics; 2004; 22(9):581-9. PubMed ID: 15209527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Taxol in small-cell and non-small-cell bronchial carcinoma].
    Med Klin Suppl; 1993 Nov; 2():14. PubMed ID: 7904715
    [No Abstract]   [Full Text] [Related]  

  • 33. Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the Population Health Model lung cancer module.
    Evans WK
    Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-56-S7-63. PubMed ID: 9194482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Costs for 5-year lung cancer survivors in a tertiary care hospital in South Korea.
    Park YS; Kim SH; Park SK; Park BJ; Kim YT; Lee SM; Yim JJ; Yoo CG; Kim YW; Han SK; Shim YS; Yang SC
    Lung Cancer; 2010 May; 68(2):299-304. PubMed ID: 19646776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-agent paclitaxel in the treatment of small cell lung cancer.
    Ettinger DS
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):16-7. PubMed ID: 9007115
    [No Abstract]   [Full Text] [Related]  

  • 36. Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression.
    Yeh JJ; Hsu WH; Wang JJ; Ho ST; Kao A
    Respiration; 2003; 70(1):32-5. PubMed ID: 12584388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Second-line chemotherapy for non-small cell lung cancer.
    Bonfill X; Serra C; Sacristán M; Nogué M; Losa F; Montesinos J
    Cochrane Database Syst Rev; 2002; (2):CD002804. PubMed ID: 12076452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost utility of chemotherapy and best supportive care in non-small cell lung cancer.
    Kennedy W; Reinharz D; Tessier G; Contandriopoulos AP; Trabut I; Champagne F; Ayoub J
    Pharmacoeconomics; 1995 Oct; 8(4):316-23. PubMed ID: 10155673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Br J Cancer; 1995 Nov; 72(5):1270-7. PubMed ID: 7577481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond survival: economic analyses of chemotherapy in advanced, inoperable NSCLC.
    Mather D; Sullivan SD; Parasuraman TV
    Oncology (Williston Park); 1998 Feb; 12(2):199-209; discussion 210, 215-6 pass. PubMed ID: 9507521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.